Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13475728 | 1.00 | CTSL (0.53) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL13093588 | 0.91 | TSHR (0.55) | CTSLCTSBCTSSCTSKHDAC3 | |
| SCHEMBL13093577 | 0.90 | HDAC3 (0.53) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL7854634 | 0.85 | CAPN1 (0.53) | CTSLCTSBCTSKCAPN1 | |
| SCHEMBL7855881 | 0.85 | CAPN1 (0.52) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7846253 | 0.84 | CAPN1 (0.50) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL8373245 | 0.83 | CAPN1 (0.54) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7288698 | 0.83 | ALOX15 (0.53) | CTSLCTSBCTSSCTSKHDAC3 | |
| SCHEMBL7288707 | 0.83 | ALOX15 (0.53) | CTSLCTSBCTSSCTSKHDAC3 | |
| SCHEMBL6463431 | 0.82 | CTSL (0.56) | CTSLCTSBCTSSCTSKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | CTSL 27/4885CTSB 24/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.